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Tamoxifen has been widely used as the standard adjuvant therapy for breast 
cancer patients with oestrogen receptor-positive status, especially in the high-
risk pre- and postmenopausal women. However, 30 to 50% of ER-positive 
breast cancer patients do not respond to tamoxifen therapy. Major challenges 
to effective tamoxifen therapy include drug resistance, and adverse events. 
Thus, this study aims to investigate the impact of pharmacogenomics and 
metabolomics in monitoring the efficacy of tamoxifen treatment in BRCA 
patients. A total of 95 tamoxifen-treated patients, and 11 untreated breast cancer 
patients from three major Malaysian ethnic groups (Malay, Chinese and Indian) 
were recruited. However, only 84 tamoxifen-treated patients with completed 
clinical data were included for clinical association analysis. Blood and plasma 
samples were collected to obtain DNA, RNA, and metabolites, and clinical data 
of the patients were also collected. Investigations proceed with the genotyping 
of CYP2D6 and ABCB1 using multiplex allele specific PCR (ASPCR) 
approach. Patients carrying CYP2D6 *10/*10 and heterozygous null allele 
(IM) showed higher risks of developing recurrence and metastasis (OR, 13.14; 
95% CI, 1.57 – 109.94; P = 0.004) compared to patients with CYP2D6*1/*1 
and *1/*10 genotypes. Patients with homozygous CC genotypes of C3435T 
had shown to have shorter recurrence time. Patients who were CYP2D6 IM 
and homozygous CC genotype of C3435T had statistically significant higher 
risks of recurrence (P = 0.002). Similarly, median time to recurrence in these 
patients was only 12 months (95%CI = 0.79 - 23.2) compared to those without 
this combination, which was 48 months (95%CI = 14.7 - 81.2). Patients with 
The leaves of S. polyanthum (Myrtaceae) and barks of O. sumatrana 
(Datiscaceae) were investigated for their chemical constituents, antioxidant 
and cytoprotective activities. Their aqueous extracts were first subjected 
to acidic hydrolysis and the organic layers were dissolved in water and 
partitioned using hexane, ethyl acetate (EtOAc) and n-butanol (BuOH). Six 
compounds (betulinic acid, ellagic acid, kaempferol, myricetin, quercetin, and 
β-sitosterol) were isolated and identified from the EtOAc and BuOH extracts 
of S. polyanthum and four compounds (quercetin, kaempferol, rutin, bryonolic 
acid) were purified from the n-butanol extract of O. sumatrana by means of 
MPLC and HPLC. The structures of the above compounds were determined by 
comparing their NMR and LCMS-TOF data with reported values. The structure 
of bryonolic acid was further confirmed by X-ray crystallography. Eleven 
essential oil components (α-caryophyllene, β-caryophyllene, caryophyllene 
oxide, 1,8-cineole, β-elemene, eugenol, eugenol acetate, isoeugenol, α-pinene, 
β- pinene, terpinen-4-ol) were identified from S. polyanthum and four fatty 
acid derivatives (linoleic acid, methyl linoleate, myristic acid, palmitic acid) 
and three steroids [5,6-dihydroegosterol, ergosta-5,8(14)-dien-3β-ol, ergosta-
5-en-3β-ol] were determined from O. sumatrana by GC-MS analysis of their 
hexane extracts. The nhexane, EtOAc and BuOH extracts were subjected to 
DPPH, FRAP and cytoprotective activities. The EtOAc and BuOH extracts of 
both plants showed potent DPPH activity with the EC50 values of 159.12 ± 
0.11μg/mL and 186.40 ± 0.58 μg/mL in S. polyanthum and 125.3 ± 0.17 μg/
mL and 136.4 ± 0.17 μg/mL in O. sumatrana, respectively. It was found that 
bryonolic acid (EC50 = 26.7 ± 0.74) only marginally quenched DPPH radical 
CYP2D6 IM and homozygous CC genotype of ABCB1 C3435T have shorter 
times to recurrence. The expression of oestrogen receptor-α and oestrogen 
receptor-β from the samples were quantitated using Real-time PCR. Absolute 
quantification of ERs reveals that the over-expression of ER-α in peripheral 
blood has positive correlation with the expression of ER-α in breast cancer 
tissue. The developed method would be useful as it is less invasive, and can 
be used to monitor a patient’s progress towards disease and drug therapy. 
Furthermore, the patients were also subjected to denaturing high performance 
liquid chromatography (dHPLC) analysis to navigate the entire exon region 
of ER-α. There were a total of 3 variants sites detected and further analysis 
on ER-α SNPs revealed that CC genotype of C325G causes an increased 
risk of recurrence (P = 0.027). Global metabolic profiling was performed by 
Quadrupole Time-of-Flight (Q-TOF) in conjunction with multivariate data 
analysis and pathway analysis. A total of eight groups of compound were 
detected to have potentials to be developed into biomarkers. Pathway analysis 
showed that steroid hormone biosynthesis, aminoacyl-tRNA biosynthesis, 
tryptophan metabolism, fatty acid metabolism, and sphingolipid metabolism 
were affected in BRCA patients. This pilot study demonstrates that the 
integration of pharmacogenomics and metabolomics into conventional 
therapeutic drug monitoring could enhance the characterization of prognosis 
as well as the patients’ response towards therapy. This would allow more 
personalized treatment to patients, thus allowing better chances of success 
in individual therapy.
but ellagic acid, myricetin, quercetin, rutin and kaempferol (92.4 ± 3.82, 74.1 
± 1.29, 76.04 ± 2.63, 76.8 ± 1.11 and 71.22 ± 1.09 (μM), respectively) showed 
strong DPPH radical scavenging activity. Then, the isolated compounds from 
S. polyanthum and O. sumatrana (myricetin, ellagic acid, betulinic acid, 
β-sitosterol, rutin, quercetin, kaempferol and bryonolic acid) were tested for 
their cytotoxic effects towards three types of cells including normal human 
embryonic liver (WRL-68), normal green monkey kidney (Vero) and human 
hepatocarcinoma (HepG2) cell lines. The cells were treated with different 
concentrations of the compounds and the results showed that the compounds 
from S. polyanthum and O. sumatrana were non-toxic towards normal cells. 
However, betulinic acid and bryonolic acid had high cytotoxicity towards 
HepG2 cells. Next, the cytoprotective effects of the isolated compounds 
against hydrogen peroxide-induced WRL-68 and Vero cells were investigated. 
Quercetin, kaempferol, myricetin, ellagic acid, betulinic acid, β-sitosterol 
and bryonolic acid showed significant protective effects compared to control 
against oxidative stress-induced WRL-68 and Vero cells. Furthermore, 
betulinic acid and bryonolic acid showed higher protective effect compared 
to ellagic acid, kaempferol, myricetin and quercetin and the activities of the 
antioxidative enzymes such as superoxide dismutase (SOD) and catalase 
(CAT) were enhanced in a dose-dependent manner. In conclusion, this study 
demonstrated that most compounds from S. polyanthum and O. sumatrana 
were cytoprotective against oxidative stress induced by H2O2 with betulinic 
acid and bryonolic acid having the highest potential to be developed to be 
used as anticancer candidates and alternative medicine.
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